Compare IMNN & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNN | CNVS |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 46.9M |
| IPO Year | 1985 | 2003 |
| Metric | IMNN | CNVS |
|---|---|---|
| Price | $3.55 | $2.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $182.61 | $9.00 |
| AVG Volume (30 Days) | 76.9K | ★ 119.7K |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $79,791,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $30.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 77.29 |
| 52 Week Low | $2.99 | $1.91 |
| 52 Week High | $41.22 | $7.39 |
| Indicator | IMNN | CNVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 64.81 |
| Support Level | $3.39 | $1.97 |
| Resistance Level | $3.77 | $2.15 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 29.27 | 97.21 |
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.